Compare MBAI & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MBAI | CWD |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.8M |
| IPO Year | N/A | 2022 |
| Metric | MBAI | CWD |
|---|---|---|
| Price | $1.62 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 161.0K | 57.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $0.20 |
| 52 Week High | $3.92 | $46.21 |
| Indicator | MBAI | CWD |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 45.16 |
| Support Level | $1.31 | $1.16 |
| Resistance Level | $1.87 | $1.54 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 33.49 | 45.77 |
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.